Published in BJU Int on June 01, 2012
Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells. BMC Cancer (2014) 0.83
5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models. Endocrinology (2013) 0.83
Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes. Patient Relat Outcome Meas (2014) 0.82
Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer. Clin Investig (Lond) (2014) 0.82
Management of advanced prostate cancer in senior adults: the new landscape. Oncologist (2012) 0.81
5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. J Urol (2014) 0.80
Bone management in Japanese patients with prostate cancer: hormonal therapy leads to an increase in the FRAX score. BMC Urol (2016) 0.75
Fracture Risk in Prostate Cancer during Hormonal Therapy. Curr Urol (2017) 0.75
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol (2010) 5.96
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol (1999) 1.98
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device. Eur J Cancer (1997) 1.84
The rectal administration of lidocaine gel and tolerance of transrectal ultrasonography-guided biopsy of the prostate: a prospective randomized placebo-controlled study. BJU Int (1999) 1.71
Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol (2006) 1.53
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer (2003) 1.48
Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol (2008) 1.29
Effects of recombinant human erythropoietin in infants with the anemia of prematurity: a pilot study. J Pediatr (1990) 1.21
Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res (1989) 1.19
Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. J Clin Oncol (1997) 1.16
Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview. Eur J Cancer (1997) 1.13
EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol (2009) 1.12
Chemotherapy in elderly patients with colorectal cancer. Ann Oncol (2001) 1.12
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat (2004) 1.12
Radiographic prognostic criteria for extracorporeal shock-wave lithotripsy: a study of 485 patients. Urology (1996) 1.11
EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. Ann Oncol (2011) 1.07
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol (2007) 1.06
Polyethylene stent blockage: a porcine model. Gastrointest Endosc (2000) 1.04
Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol (2007) 1.02
Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG). Ann Oncol (2004) 1.00
[Schwannoma and the urinary tract. Concerning a tumor of the obdurator nerve]. Prog Urol (1999) 0.95
Commission of the European Communities "Europe Against Cancer" Programme. European school of oncology advisory report. Cancer treatment in the elderly. Eur J Cancer (1993) 0.95
Assessment of the older cancer patient. Hematol Oncol Clin North Am (2000) 0.94
A prospective radiological anatomical study of the variations of the position of the colon in the left pararenal space. Surg Radiol Anat (2001) 0.93
[The French linguistic validation of the Ureteric Stent Symptom Questionnaire (USSQ)]. Prog Urol (2009) 0.92
Implantable electrophysiologic cardiac device infections: a risk factor analysis. Eur J Clin Microbiol Infect Dis (2012) 0.92
A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer (2014) 0.92
New directions in the treatment of colorectal cancer: a look to the future. Eur J Cancer (2000) 0.89
Phase II study of tauromustine in malignant glioma. Eur J Cancer (1992) 0.88
Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer. Urology (2001) 0.87
[Renal cancer and late pancreatic metastases. Apropos of 3 cases and review of the literature]. Prog Urol (1998) 0.85
Carcinoma of the penis in lichen sclerosus atrophicus. A case report. Eur Urol (1990) 0.85
Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Eur J Cancer (1995) 0.85
[Effects by androgen suppression with luteinizing hormone on cognitive functions in men treated for cancer of prostate]. Prog Urol (2008) 0.84
Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia. Oncology (2011) 0.84
Influence of preoperative hydronephrosis on the outcome of urothelial carcinoma of the upper urinary tract after nephroureterectomy: the results from a multi-institutional French cohort. World J Urol (2012) 0.83
Urine PSA is not useful for detecting prostate cancer? Urology (1998) 0.83
Adjuvant chemotherapy in the elderly. Ann Oncol (2003) 0.83
Elective surgery for gastrointestinal tumours in the elderly. Ann Oncol (1997) 0.82
Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. Urology (2001) 0.82
An effective five-drug antiemetic combination for prevention of chemotherapy-related nausea and vomiting. Experience in eighty-four patients. Cancer Chemother Pharmacol (1986) 0.82
Optimal selection of antiemetics in children receiving cancer chemotherapy. Support Care Cancer (1998) 0.81
Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Cancer Chemother Pharmacol (1995) 0.81
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol (2017) 0.80
Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors. Crit Rev Oncol Hematol (2005) 0.80
Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center. Eur J Cancer (1995) 0.80
[French translation and linguistic validation of the questionnaire Bladder Cancer Index (BCI)]. Prog Urol (2012) 0.79
[Short or long schemes of antibiotic prophylaxis for prostate biopsy. A multicentre prospective randomised study]. Prog Urol (2008) 0.79
Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology (2001) 0.78
[Bacillus Calmette-Guerin maintenance treatment in non-invasive bladder tumors: 1 year follow-up results of multicenter URO-BCG-4 trial]. Prog Urol (2013) 0.78
[Tolerance and efficiency of intravesical instillation of Calmette-Guérin in the prophylactic treatment of superficial bladder tumors, using a maintenance treatment]. Prog Urol (2001) 0.78
Who should receive a 5-HT3 antagonist? Lancet (1992) 0.78
[T1 bladder carcinoma: prognostic value of the muscularis mucosae invasion (T1a/T1b). A multicenter study by the French Urological Association (CCAFU)]. Prog Urol (2010) 0.78
[Efficiency and tolerance of intermittent self-dilatation after internal urethrotomy for urethral strictures]. Prog Urol (2011) 0.78
Early clinical trial of MDL 73.147 EF: a new 5-HT3-receptors antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann Oncol (1993) 0.77
Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Ann Oncol (1991) 0.77
Loss of heterozygosity for the short arm of chromosome 11 (11p15) in human milk epithelial cells immortalized by microinjection of SV40 DNA. Cancer Res (1991) 0.77
Screening and chemoprevention. Crit Rev Oncol Hematol (1998) 0.77
Treatment implications for radiation-induced nausea and vomiting in specific patient groups. Eur J Cancer (2004) 0.77
[Long-term outcome of renal transplantation: impact of surgical complications on graft survival]. Prog Urol (2012) 0.77
[Prostatic cancer before the age of 50--report of 7 cases]. Prog Urol (1991) 0.76
[Survival is associated with time to reach PSA nadir (DAN) and the ratio DAN/nadir value after androgen deprivation for prostate cancer]. Prog Urol (2011) 0.76
Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. Ann Oncol (1997) 0.76
Cancer treatment in the elderly: the need for a better organization. Ann Oncol (2007) 0.76
[AFU recommendations 1998. "Committee on Cancer of the French Association of Urology"]. Prog Urol (2002) 0.76
[Recommendations Onco-Urology 2010: Urothelial tumors]. Prog Urol (2010) 0.75
Re: Subcutaneous urinary diversions for palliative treatment of pelvic malignancies. J Urol (1996) 0.75
Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade? Br J Cancer (2002) 0.75
[Reality and hope: a critical approach to an antiemetic drug]. Bull Cancer (1993) 0.75
Clinical efficacy of cancer subcutaneous immunotherapy with interleukin-2 in relation to the pretreatment levels of tumor growth factor insulin-like growth factor-1. Tumori (1996) 0.75
Cancer treatment and old people. Lancet (1991) 0.75
Asymptomatic inflammation and/or infection in benign prostatic inflammation. BJU Int (2000) 0.75
[Ectopic ureteral orifice into the seminal duct with homolateral renal agenesis: contribution of ultrasonography]. Prog Urol (1993) 0.75
[Experimental study of urinary calculi fragmentation with pulsed laser shockwave, based on their chemical composition]. Prog Urol (1995) 0.75
[Genito-urinary injuries. Sequelae. Medico-legal aspects]. Chirurgie (1996) 0.75
[Impotence in pelvic fractures. Report of 16 cases]. Prog Urol (1993) 0.75
[Can the prostatic capsule be preserved during cystectomy for bladder tumors: a study of urethral and prostatic involvement in the cystectomy specimens]. Prog Urol (1998) 0.75
Potential pitfall in CT and sonographic evaluation of suspected lymphoma. AJR Am J Roentgenol (1982) 0.75
[Multiple myeloma of the testis]. Prog Urol (1995) 0.75
[Simplified vesico-urethral anastomosis after radical retropubic prostatectomy for cancer. A preliminary comparative study]. J Urol (Paris) (1995) 0.75
[Cerebral metastases of testicular neoplasms. Apropos of 2 cases and review of the literature]. Neurochirurgie (1994) 0.75
[Impact of genital prolapse on the upper urinary tract]. Prog Urol (2000) 0.75
A double-blind crossover study comparing prophylactic intravenous granisetron alone or in combination with dexamethasone as antiemetic treatment in controlling nausea and vomiting associated with chemotherapy. Eur J Cancer (1997) 0.75
[Vesico-urethral anastomosis after radical prostatectomy in cancer: Vest-Mayo's simplified technique]. Prog Urol (1994) 0.75
Familial ureteral duplication and ureterocele: two sisters and their father. Eur Urol (2000) 0.75
Promises and challenges of oncology and hematology, including geriatric oncology. Crit Rev Oncol Hematol (2004) 0.75
[Orbital metastasis of prostatic cancer. Clinical and therapeutic aspects. Apropos of a case (clinical case)]. Chirurgie (1997) 0.75
Gynaecologic cancers. Crit Rev Oncol Hematol (1998) 0.75
[Idiopathic vaginal hydrocele. Treatment using a sclerosing injection of minocycline]. Prog Urol (1993) 0.75
[Results of extracorporeal lithotripsy with ultrasonography-guided hydroelectric lithotriptor: study on 546 patients, prognosis factors]. Prog Urol (1995) 0.75
Histiocytic necrotizing lymphadenitis or Kikuchi's disease. Anatomo-clinical study of 4 cases. Nouv Rev Fr Hematol (1990) 0.75
[The treatment of stage I malignant non-seminoma tumors of the testis without systematic lumbo-aortic dissection. Results of a study begun 20 years ago. Apropos of 21 cases]. Prog Urol (1994) 0.75
[A technical device for the percutaneous extraction in monobloc of various renal calculi larger than 10 mm]. Prog Urol (1994) 0.75
Weekly carboplatin and VM-26 for elderly patients with small-cell lung cancer. Ann Oncol (1994) 0.75
Prognostic value of histological grade and nuclear grade in renal adenocarcinoma. J Urol (1994) 0.75
[Percutaneous nephrolithotomy after failure of extracorporeal shockwave lithotripsy. Indications, results, perspectives]. Prog Urol (1993) 0.75